Sugi Predict

Sugi Predict / Compounds / SCHEMBL2463238

SCHEMBL2463238

SCHEMBL2463238

N[N+]12C=CN=CC1=C(C1=CC=C1)N=C2c1cccc(OCc2cccc(NC(=O)Cc3ccncc3)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 10/20 0.41
▸ SIRT1 Q96EB6 9/20 0.41
▸ SIRT3 Q9NTG7 8/20 0.41
▸ HTR1A P08908 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ NR1H4 Q96RI1 1/20 0.34
▸ F10 P00742 3/20 0.34
▸ PRKACA P17612 1/20 0.34
▸ ROCK1 Q13464 1/20 0.34
▸ USP2 O75604 1/20 0.33
▸ SLC1A3 P43003 1/20 0.33
▸ SLC1A2 P43004 1/20 0.33
▸ SLC1A1 P43005 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2460274 0.91 SIRT2 (0.47) SIRT2SIRT1SIRT3NR1H4
SCHEMBL2458314 0.90 HTR1A (0.39) SIRT2SIRT1SIRT3HTR1ADRD2
SCHEMBL2464327 0.88 LTA4H (0.37) SIRT2SIRT1SIRT3
SCHEMBL2460413 0.88 SIRT2 (0.42) SIRT2SIRT1SIRT3NR1H4
SCHEMBL2463557 0.86 NR1H4 (0.49) SIRT2SIRT1SIRT3NR1H4
SCHEMBL2460129 0.85 NR1H4 (0.35) SIRT2SIRT1SIRT3NR1H4
SCHEMBL2460569 0.85 NR1H4 (0.35) SIRT2SIRT1SIRT3NR1H4
SCHEMBL2462556 0.84 ALDH1A1 (0.43) SIRT2SIRT1SIRT3
SCHEMBL2457071 0.84 MAP4K4 (0.40) SIRT2NR1H4
SCHEMBL2459648 0.82 MRGPRX4 (0.50) NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 — — US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 SIRT2 1144/4885SIRT1 966/4885SIRT3 881/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 SIRT2 1144/4885SIRT1 966/4885SIRT3 881/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 SIRT2 1144/4885SIRT1 966/4885SIRT3 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.